In school music education efficiency or effectiveness-a review from the Early Republican Period times new roman

Bu çalışmada Erken Cumhuriyet Dönemi’nden günümüze etkililiği sağlayan müzik dersi yöntem ve uygulamalarının kullanımını incelemek amacıyla, 1923-2023 yılları arasında oluşturulmuş on adet müzik dersi ilkokul-ortaokul öğretim programı ve 1923-2023 yılları arasında oluşturulmuş on yedi adet ilkokul-ortaokul müzik ders kitabı ile bir adet ilkokul müzik dersi öğrenci çalışma kitabı doküman analizi yöntemi ile görsel-yapısal içerik tasarımı, yaratıcı/disiplinlerarası çalışmalar, teknolojik uygulamalar, çalgı eğitimi, popüler müzik bakımından incelenmiştir. Araştırma sonucunda Erken Cumhuriyet Dönemi’nden itibaren oluşturulan ilkokul-ortaokul müzik dersi öğretim programları ve ders kitaplarının görsel-yapısal içerik tasarımı, yaratıcı/disiplinlerarası çalışmalar, teknolojik uygulamalar bakımından öncelikle 1960 yılında gelişim göstermeye başladığı ve özellikle 1990’lı ve 2000’li yıllarla birlikte gelişim hızının belirgin biçimde arttığı, popüler müziklerin eklenmesi ve çalgı eğitimi uygulamaları açısından Erken Cumhuriyet Dönemi’nden itibaren etkin bir gelişim sağlanamadığı çıkarımına varılmıştır.In this study, in order to examine the use of effective music lesson methods and practices from the Early Republican Period to the present, ten music lesson primary-secondary school curricula created between 1923-2023, seventeen primary-secondary school music textbooks created between 1923-2023, and one primary-secondary school music lesson student workbook were examined in terms of visual-structural content design, creative/interdisciplinary studies, technological applications, instrument education, popular music by document analysis method. As a result of the research, it was concluded that primarysecondary school music course curricula and textbooks created since the Early Republican Period started to develop in 1960 in terms of visual-structural content design, creative/interdisciplinary studies, technological applications, and that this development rate increased significantly especially in the 1990s and 2000s, and that an effective development has not been achieved since the Early Republican Period in terms of the addition of popular music and instrument training practices

Self-healing time estimation of abandoned mine areas using remote sensing

Lately, remote sensing has been an effective tool for monitoring the Earth and environmental changes. Landsat with its legacy is providing available data for time-based research. The aim of this paper is to estimate the time of the self-healing progress of an abandoned mine area using Landsat satellite images. In this study, five Landsat satellite images were used. As a study area, the abandoned Damjan mine in the southeastern part of the Republic of N. Macedonia has been chosen. Normalized Difference Vegetation Index (NDVI) and Normalized Difference Water Index (NDWI) values were used to classify Landsat images into barren land, bared soil, mixture of vegetation, vegetation, and water bodies. The NDVI values lower than zero are considered to be the area affected by the mine. The healing of the mine has been established using the annual growth rate analysis. It was found that the area has been healing approximately 10 % every year and a prediction was made for the study area till the year 2030

A new generation, promising engineering material: Cubic boron nitride c-BN

In order to meet the design requirements and expanding demands in various engineering fields, it is essential to incorporate new technological improvements in material sciences into existing processes and applications. This involves engineering new material systems and improving existing ones towards higher strength, toughness and wear resistance. In this context, cubic boron nitride c-BN , which is a special polymorph of boron nitride, seems to be a high-potential candidate for engineering solutions due to its great mechanical and chemical properties. In this article, advantages and disadvantages of c-BN material system are presented with respect to our ongoing research efforts. The preliminary results about the characterization study of thin film c-BN coatings with Raman spectroscopy are also presente

S 4

Numerical solution of the transport equation for monoenergetic neutrons scattered isotropically through the medium of a finite homogeneous slab is studied for the determination of the eigenvalues. After obtaining the discrete ordinates form of the transport equation, separated homogeneous and particular solutions are formed and then the eigenvalues are calculated using the Gauss-Legendre quadrature set. Then, the calculated eigenvalues for various values of the c0, the mean number of secondary neutrons per collision, are given in the tables

2016 UEFA European Championship: Pass and shot association

The purpose of this study is to analyze the association between technical features such as goal, pass, shot, ball possession and ball stealing, and the goals scored in matches played by teams who qualified out of the group (n=16) and who could not (n=8) in 2016 UEFA European Championship. The data of the study were obtained by using computerized multiple camera surveillance system (Prozone). SPSS 22.0 program was used for the statistical analyses of this study. Independent T test was used to compare the parameters of teams who qualified out of the team and those who could not, while Pearson correlation analysis was used to analyze the association between variables. When the total shot parameters per match apart from shots, total pass, total pass to the third zone and ball stealing total data were compared, significant difference was found (p<0.05). In all of the shot parameters, especially in total goals scored and total shots on target (r=0.903), a positive high association was found in total ball stealing (r=0.796), total pass (r=0.753), total forward pass (r=0.819) and total pass to the third zone (r=0.748), while a negative intermediate association was found in average pass length per match (34+M) (r=-0.449). When the results were examined, it can be said that the teams who qualified out of the game can use technical properties effectively. It can be stated that in order to be successful in elite tournaments in the world, analysis practices should be taken more into consideration as well as technical and tactical practices

Welcome to the December 2023 Issue (Vol:29, No:4) and Current News of the European Journal of Therapeutics

Dear Colleagues, In this editorial, we would like to share with you important developments in the European Journal of Therapeutics (Eur J Ther). First of all, as the editorial team, we would like you to know that we hold frequent meetings to benefit our esteemed colleagues and continue to work with great devotion in line with our goal of taking the journal further. We have previously shared with you that we have applied to many indexes. It is with great pleasure that we would like to inform you that in the last few months, more of our index applications have been approved. Index Copernicus, as a result of this application, the ICV 2022 value of our journal was determined to be 100 (approved 2023-10-31) [1] BASE (Bielefeld Academic Search Engine) (approved 2023-11-30) [2] Sherpa Romeo (approved 2023-09-27) [3] MIAR (approved 2023-10-16) [4] All indexes in our journal are currently included on the journal web page [5]. As the editorial team, we would like to inform you that we have determined a policy on this issue for our journal [6], taking into account the recommendations of important international ethics committees such as the Committee on Publication Ethics (COPE) [7] and the World Association of Medical Editors (WAME) [8], which have recently become a trendy topic of discussion about AI chatbots and academic studies prepared with the support of such tools. As you know, when our journal was founded in 1990 [9], it was published in two yearly issues. It is an essential responsibility for us to carry our journal, which continued its publication life with three issues a year in 2009 [10] and four issues a year in 2014 [11]. With your valuable support, we would like to announce that we will increase our journal to 6 issues a year as of 2024 (February, April, June, August, October and December) with the rapidly growing progress of our journal. Unfortunately, we cannot share the names of the referees who made significant contributions to our journal in 2023 due to the changes in the article submission interface during the year and the inaccessibility of some data in the previous interface. However, we would like to emphasize again that we are grateful to all of them for their valuable contributions. Moreover, to expand our journal's referee list, we would like to remind you that competent academics who volunteer in this regard can fill out the “Become a Reviewer for the European Journal of Therapeutics” form [12]. Finally, we would like to point out that we have strengthened our editorial team with an academician competent in dentistry, Fatih Sari, DDS, PhD. Fatih Sari, DDS, PhD, is a new Editorial Board Member of the Eur J Ther. Dr. Sari is an Associate Professor in the Department of Prosthodontics at the Gaziantep University Faculty of Dentistry. He is a Vice Dean of the Faculty of Dentistry and Head of Clinical Departments. Dr. Sari is a prosthodontist and a member of the Turkish Dental Association. He has experience in implant-supported fixed prostheses, Cad/Cam applications and dental materials. We look forward to being able to offer you a large number of high-quality and valuable articles over the coming year. In addition, we would like to thank the readers, authors and reviewers of the Eur J Ther for their continuous support. Sincerely yours

Discontinuation of RAAS Inhibition in Children with Advanced CKD

Background and objectives Although renin-angiotensin-aldosterone system inhibition (RAASi) is a cornerstone in the treatment of children with CKD, it is sometimes discontinued when kidney function declines. We studied the reasons of RAASi discontinuation and associations between RAASi discontinuation and important risk markers of CKD progression and on eGFR decline in the Cardiovascular Comorbidity in Children with CKD study. Design, setting, participants,& measurements In this study, 69 children with CKD(67% male, mean age 13.7 years, mean eGFR 27 ml/min per 1.73m(2)) who discontinued RAASi during prospective follow-up were included. Initial change in BP, albuminuria, and potassium after discontinuation were assessed (median time 6 months). Rate of eGFR decline (eGFR slope) during a median of 1.9 years before and 1.2 years after discontinuation were estimated using linear mixed effects modeling. Results Physician-reported reasons for RAASi discontinuation were increase in serum creatinine, hyperkalemia, and symptomatic hypotension. After discontinuation of RAASi, BP and albuminuria increased, whereas potassium decreased. eGFR declined more rapidly after discontinuation of RAASi (23.9 ml/min per 1.73m2 per year; 95% confidence interval, 25.1 to 22.6) compared with the slope during RAASi treatment (21.5 ml/min per 1.73 m(2) per year; 95% confidence interval, 22.4 to 20.6; P=0.005). In contrast, no change in eGFR slope was observed in a matched control cohort of patients in whom RAASi was continued. Conclusions Discontinuation of RAASi in children with CKD is associated with an acceleration of kidney function decline, even in advanced CKD

Serum indoxyl sulfate concentrations associate with progression of chronic kidney disease in children

The uremic toxins indoxyl sulfate (IS) and p-cresyl sulfate (pCS) accumulate in patients with chronic kidney disease (CKD) as a consequence of altered gut microbiota metabolism and a decline in renal excretion. Despite of solid experimental evidence for nephrotoxic effects, the impact of uremic toxins on the progression of CKD has not been investigated in representative patient cohorts. In this analysis, IS and pCS serum concentrations were measured in 604 pediatric participants (mean eGFR of 27 ± 11 ml/min/1.73m2) at enrolment into the prospective Cardiovascular Comorbidity in Children with CKD study. Associations with progression of CKD were analyzed by Kaplan-Meier analyses and Cox proportional hazard models. During a median follow up time of 2.2 years (IQR 4.3-0.8 years), the composite renal survival endpoint, defined as 50% loss of eGFR, or eGFR <10ml/min/1.73m2 or start of renal replacement therapy, was reached by 360 patients (60%). Median survival time was shorter in patients with IS and pCS levels in the highest versus lowest quartile for both IS (1.5 years, 95%CI [1.1,2.0] versus 6.0 years, 95%CI [5.0,8.4]) and pCS (1.8 years, 95%CI [1.5,2.8] versus 4.4 years, 95%CI [3.4,6.0]). Multivariable Cox regression disclosed a significant association of IS, but not pCS, with renal survival, which was independent of other risk factors including baseline eGFR, proteinuria and blood pressure. In this exploratory analysis we provide the first data showing a significant association of IS, but not pCS serum concentrations with the progression of CKD in children, independent of other known risk factors. In the absence of comorbidities, which interfere with serum levels of uremic toxins, such as diabetes, obesity and metabolic syndrome, these results highlight the important role of uremic toxins and accentuate the unmet need of effective elimination strategies to lower the uremic toxin burden and abate progression of CKD

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe